chartexchange

Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

PR Newswire | Nov 5, 2026 9:27 PM EST

HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibody ivonescimab in the perioperative treatment of resectable non-small cell lung cancer (NSCLC) have been...

Read original article